Regeneron says a single dose of its antibody cocktail reduced the risk of contracting Covid-19 by 81.6%.
Single dose of REGEN-COV (1,200 mg subcutaneous) reduced the risk of COVID-19 by 81.6% during the pre-specified follow-up period (months 2-8), maintaining the 81.4% risk reduction previously reported during month 1
During the 8-month assessment period there were 0 hospitalizations for COVID-19 in the REGEN-COV group and 6 in the placebo group
The fully human antibodies in REGEN-COV were developed to provide long-lasting protective effects without any artificial mutations or sequences
https://www.cnbc.com/video/2021/11/08/regeneron-says-single-dose-of-covid-antibody-cocktail-provides-long-term-protection.html